2021
DOI: 10.1002/14651858.cd006687.pub4
|View full text |Cite
|
Sign up to set email alerts
|

Vasodilators for primary Raynaud's phenomenon

Abstract: 5. Art. No.: CD006687.. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
7
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
2
2

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(8 citation statements)
references
References 74 publications
0
7
0
1
Order By: Relevance
“…For mild cases, avoidance of triggers like cold or emotional stress might be sufficient, but severe vasospastic attacks require pharmacological interventions with calcium channel blockers as first line response 6 . However, overall effectiveness of calcium channel blockers 5 or alternative vasodilatory medications such as angiotensin receptor blockers, selective serotonin reuptake inhibitors, or phosphodiesterase-5 inhibitors is limited 6,7 and much hope put in selective α 2C -adrenoreceptors inhibitors has not been supported by a recent trial 36 . A staggering characteristic of the ADRA2A locus was the specificity in phenome-wide screens and comprehensive database lookups, which indicated a RP-specific effect.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…For mild cases, avoidance of triggers like cold or emotional stress might be sufficient, but severe vasospastic attacks require pharmacological interventions with calcium channel blockers as first line response 6 . However, overall effectiveness of calcium channel blockers 5 or alternative vasodilatory medications such as angiotensin receptor blockers, selective serotonin reuptake inhibitors, or phosphodiesterase-5 inhibitors is limited 6,7 and much hope put in selective α 2C -adrenoreceptors inhibitors has not been supported by a recent trial 36 . A staggering characteristic of the ADRA2A locus was the specificity in phenome-wide screens and comprehensive database lookups, which indicated a RP-specific effect.…”
Section: Discussionmentioning
confidence: 99%
“…Management of RP is predominantly limited to avoidance of triggers and evidence for medical treatment is generally weak. Repurposed vasodilators are the first line treatment if pharmacological intervention is required due to progressive frequency of vasospastic attacks 6 , although only calcium channel blockers have so far been shown to lead to a significant and reproducible reduction in the frequency of vasospastic attacks 7 . However, use of systemic drugs for localized symptoms puts patients at risk of generalised adverse effects, such as hypotension.…”
Section: Introductionmentioning
confidence: 99%
“…Although it is generally uncertain whether cilostazol is safe and effective for use in children, a clinical trial testing the effects of cilostazol for the treatment of juvenile Raynaud’s Phenomenon, a blood vessel disorder in children, has been completed with no significant beneficial effects discovered [67]. On the other hand, cilostazol has been tested effective in a rat model of prenatal valproic acid-induced autism spectrum disorder [68] and hence proposed as an adjunctive therapy for the children with autism spectrum disorder [69].…”
Section: Discussionmentioning
confidence: 99%
“…3 Although calcium channel blockers have been shown to improve symptoms, the evidence for second-line treatment options is less convincing. [4][5][6] Refractory cases of RP are common, often leading patients to seek procedural interventions.…”
Section: Introductionmentioning
confidence: 99%
“…First-line management is lifestyle modifications, followed by medical interventions such as calcium channel blockers, and second-line options are phosphodiesterase 5 inhibitor inhibitors, angiotensin receptor blocker / angiotensin converting enzyme inhibitor inhibitors, selective serotonin receptor inhibitor, and alpha channel blockers 3 . Although calcium channel blockers have been shown to improve symptoms, the evidence for second-line treatment options is less convincing 4–6 . Refractory cases of RP are common, often leading patients to seek procedural interventions.…”
Section: Introductionmentioning
confidence: 99%